What are the contraindications for taking resmetirom?

Resmetirom-Rezdiffra, as a new metabolic targeted drug, has shown a breakthrough effect in improving non-alcoholic steatohepatitis, but it also has certain contraindications in clinical use. One of its most important contraindications is that it should not be used in patients with decompensated cirrhosis. The reason is that the liver function reserve of such patients has been severely damaged, and the metabolism and elimination ability of the drug has decreased, which may lead to the accumulation of the drug in the body, thus increasing the risk of side effects. In addition, the drug's regulatory mechanism on hepatic lipid metabolism may cause unpredictable adverse reactions in such patients, so it is clearly included in the contraindication group.

In addition to decompensated cirrhosis, patients with a theoretical severe allergic reaction to any component of rismetirol should also avoid its use, a common contraindication for all oral medications. Clinicians will also be more cautious in evaluating whether the use of this product is suitable for individuals with other severe liver diseases, acute liver failure, or previous high-risk drug-induced liver injury. Since the core target of resmetirol is the liver, its contraindications are mostly closely related to liver function status, which is consistent with the general rule of some metabolic drugs.

At the same time, what needs to be paid attention to is the safety of female patients during pregnancy and lactation. Although there is currently a lack of large-scale clinical data to clarify its risks, based on the pharmacological mechanism and international drug management regulations, clinical use of this drug during pregnancy and lactation is usually avoided to reduce the potential impact on the fetus or infant. Overall, although the contraindications of resmetirol are not as complicated as those of traditional chemotherapy drugs, the restrictions for patients with severely impaired liver function are very clear. In the future, as more real-world research accumulates, the scope of the taboo may be supplemented in more detail.

Reference materials:https://www.drugs.com/monograph/resmetirom.html